803 results on '"Jager, Agnes"'
Search Results
2. Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial
3. Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?
4. High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
5. Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
6. Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients
7. CBD-oil as a potential solution in case of severe tamoxifen-related side effects
8. Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival
9. Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels
10. High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation
11. A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: The importance of trial design
12. Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
13. HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study
14. Clinical decision support systems for multidisciplinary team decision-making in patients with solid cancer: Composition of an implementation model based on a scoping review
15. Rare germline copy number variants (CNVs) and breast cancer risk
16. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment
17. FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women
18. PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial
19. The interplay between tamoxifen and endoxifen plasma concentrations and coagulation parameters in patients with primary breast cancer
20. Mendelian randomisation study of smoking exposure in relation to breast cancer risk
21. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element
22. Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study
23. Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association ConsortiumBreast Cancer Risk Factors and Survival By Tumor Subtype
24. Exploring the Psychosocial Needs of Adolescents Whose Parent Is Diagnosed With Breast Cancer
25. Cognitive function in patients with HR+ advanced breast cancer treated with endocrine therapy with or without CDK4/6 inhibitors in the SONIA trial.
26. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers
27. Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale
28. Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial
29. Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study
30. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests
31. HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
32. Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?
33. Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer
34. Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial
35. The changing microRNA landscape by color and cloudiness: a cautionary tale for nipple aspirate fluid biomarker analysis
36. Detection of Drug-induced Interstitial Lung Disease Caused by Cancer Treatment Using Electronic Nose Exhaled Breath Analysis.
37. Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer
38. Figure S6 from Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
39. Supplementary Data 1 from Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
40. Data from Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
41. Reduction in potentially inappropriate end-of-life hospital care for cancer patients during the COVID-19 pandemic: A retrospective population-based study
42. The added value of H2 antagonists in premedication regimens during paclitaxel treatment
43. Effect of Case-Mix and Random Variation on Breast Cancer Care Quality Indicators and Their Rankability
44. From Multiple Quality Indicators of Breast Cancer Care Toward Hospital Variation of a Summary Measure
45. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
46. Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study
47. Continuity of care for patients with de novo metastatic cancer during the COVID‐19 pandemic: A population‐based observational study.
48. The effect of (neo)adjuvant chemotherapy on long‐term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study.
49. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
50. Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.